EUVIMEDEUVIMED entdecken
Open Access

Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients

Steven T Bird, Elizabeth R Smith, Kate Gelperin, Tae Hyun Jung, Aliza Thompson, Rekha Kambhampati, Hai Lyu, Henu Zhao, Yueqin Zhao, Yunfan Zhu, Olivia Easley, Ali Niak und 5 weitere

JAMA · 13.02.2024 · 331 (6) · 491

DOI: 10.1001/jama.2023.28239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 13.02.2024. Verfasst von Steven T Bird und 16 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Hauptthemen laut MEDLINE: Hypocalcemia, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Dialysis-dependent patients experience high rates of morbidity from fractures, yet little evidence is available on optimal treatment strategies. Chronic kidney disease–mineral and bone disorder is nearly universal in dialysis-dependent patients, complicating diagnosis and treatment of skeletal fragility.

Objective

To examine the incidence and comparative risk of severe hypocalcemia with denosumab compared with oral bisphosphonates among dialysis-dependent patients treated for osteoporosis. Design, Setting, and Participants Retrospective cohort study of female dialysis-dependent Medicare patients aged 65 years or older who initiated treatment with denosumab or oral bisphosphonates from 2013 to 2020. Clinical performance measures including monthly serum calcium were obtained through linkage to the Consolidated Renal Operations in a Web-Enabled Network database. Exposures Denosumab, 60 mg, or oral bisphosphonates. Main Outcomes and Measures Severe hypocalcemia was defined as total albumin-corrected serum calcium below 7.5 mg/dL (1.88 mmol/L) or a primary hospital or emergency department hypocalcemia diagnosis (emergent care). Very severe hypocalcemia (serum calcium below 6.5 mg/dL [1.63 mmol/L] or emergent care) was also assessed. Inverse probability of treatment-weighted cumulative incidence, weighted risk differences, and weighted risk ratios were calculated during the first 12 treatment weeks.

Results

In the unweighted cohorts, 607 of 1523 denosumab-treated patients and 23 of 1281 oral bisphosphonate–treated patients developed severe hypocalcemia. The 12-week weighted cumulative incidence of severe hypocalcemia was 41.1% with denosumab vs 2.0% with oral bisphosphonates (weighted risk difference, 39.1% [95% CI, 36.3%-41.9%]; weighted risk ratio, 20.7 [95% CI, 13.2-41.2]). The 12-week weighted cumulative incidence of very severe hypocalcemia was also increased with denosumab (10.9%) vs oral bisphosphonates (0.4%) (weighted risk difference, 10.5% [95% CI, 8.8%-12.0%]; weighted risk ratio, 26.4 [95% CI, 9.7-449.5]). Conclusions and Relevance Denosumab was associated with a markedly higher incidence of severe and very severe hypocalcemia in female dialysis-dependent patients aged 65 years or older compared with oral bisphosphonates. Given the complexity of diagnosing the underlying bone pathophysiology in dialysis-dependent patients, the high risk posed by denosumab in this population, and the complex strategies required to monitor and treat severe hypocalcemia, denosumab should be administered after careful patient selection and with plans for frequent monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypocalcemiaBone Density Conservation AgentsOsteoporosisUnited StatesHumansAgedFemaleDenosumabCalciumRetrospective StudiesRenal DialysisMedicareDiphosphonates

Substanzen

DenosumabBone Density Conservation AgentsCalciumDiphosphonates

Autor:innen und Institutionen

  • Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Acumen LLC, Burlingame, California.
  • Division of Biometrics, Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Division of Cardiology and Nephrology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Division of General Endocrinology, Office of Cardiology, Hematology, Endocrinology, and Nephrology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Centers for Medicare & Medicaid Services, Washington, DC.

Zitieren

APA

Bird, S. T., Smith, E. R., Gelperin, K., Jung, T. H., Thompson, A., Kambhampati, R., Lyu, H., Zhao, H., Zhao, Y., Zhu, Y., Easley, O., Niak, A., Wernecke, M., Chillarige, Y., Zemskova, M., Kelman, J. A., & Graham, D. J. (2024). Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients. JAMA, 331(6), 491. https://doi.org/10.1001/jama.2023.28239

Vancouver

Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R, et al. Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients. JAMA. 2024;331(6):491. doi:10.1001/jama.2023.28239

BibTeX
@article{Bird2024,
  author = {Bird, Steven T and Smith, Elizabeth R and Gelperin, Kate and Jung, Tae Hyun and Thompson, Aliza and Kambhampati, Rekha and Lyu, Hai and Zhao, Henu and Zhao, Yueqin and Zhu, Yunfan and Easley, Olivia and Niak, Ali and Wernecke, Michael and Chillarige, Yoganand and Zemskova, Marina and Kelman, Jeffrey A and Graham, David J},
  title = {Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {6},
  pages = {491},
  doi = {10.1001/jama.2023.28239}
}
Kostenlos starten →